PapersPMID:42588182
Untargeted 1H-NMR Metabolomics Identifies Candidate Metabolic Changes Associated with Watercress (Nasturtium officinale R.Br.) Supplementation in Adults with Low-to-Moderate Cardiovascular Risk: A Randomized Placebo-Controlled Trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 4 weeks
- Dose studied, every finding
- 8 g/day dried watercress powder in 500 mg capsules for 28 days (estimated 195 mg total glucosinolates/day)
- Population, every finding
- Thai adults aged 40-59 years with low-to-moderate cardiovascular risk (predicted 10-year Framingham CVD risk <15%) and at least one cardiometabolic risk factor, taking no documented medications
No finding here moved its endpoint.
What did not
How to read these marks →“No significant group × visit interactions were observed for HDL-C or triglycerides (Table 2).”
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Thai adults aged 40–59 years with low-to-moderate cardiovascular disease risk and at least one cardiometabolic risk factor
- Participants
- 26
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 49